Healthcare Industry News: kidney disease
News Release - November 3, 2008
AtCor Medical Introduces New Portable Systems for Measuring Central Blood Pressure, Pulse Wave Velocity and Heart Rate VariabilityGold Standard SphygmoCor(R) Technology for Use in Any Clinical Setting
ITASCA, IL--(Healthcare Sales & Marketing Network)--Nov 3, 2008 -- AtCor Medical Inc. (ASX:ACG.AX ) today announced that it will introduce new, lightweight, portable SphygmoCor® CP, SphygmoCor® CPV and SphygmoCor® CPVH systems at Renal Week 2008, the annual scientific meeting of the American Society of Nephrology (November 6-8) and the American Heart Association Scientific Sessions November (9-12).
The company's SphgymoCor technology is considered the global standard for noninvasive central blood pressure and pulse wave velocity assessment. SphygmoCor technology, featured in hundreds of published peer-reviewed studies, is in use in leading medical centers and in clinical trials worldwide.
AtCor Medical developed its new, more compact SphygmoCor systems, available in different configurations, to make assessing central blood pressure, pulse wave velocity and heart rate variability easier and more convenient in settings where space is at a premium -- at bedside in hospitals, in patient exam rooms in physicians' offices, ERs, mobile patient screening vans, and in home care. All three tests are used in evaluating cardiovascular status and in managing patient care.
75% reduction in system size and weight -- with added capabilities
The new SphygmoCor systems, approximately 25% the size and weight of AtCor's first generation systems, offer the same functionality as the company's earlier SphgymoCor Px and Vx systems with added portability, less power consumption and enhanced electronics. The SphygmoCor CPV system, which performs both central blood pressure and pulse wave velocity assessments, can be also be configured to perform heart rate variability analyses, a new system capability. Heart rate variability testing is used in assessing cardiovascular risk.
"In the United States, our sales of systems intended for clinical, rather than research and clinical trials use, grew by over 50% in fiscal 2008," said Duncan R. Ross, AtCor Medical President and CEO. "Clinicians can use the new SphygmoCor CP systems wherever the patient may be treated."
Unmasking The Very Silent Killer -- Elevated Central Blood Pressure
A large recently published clinical study found that 70% of patients with high normal blood pressure had central blood pressures equivalent with those of patients diagnosed with Stage 1 Hypertension. Others studies have shown that elevated central pressure is associated with increased risk of heart attack, stroke and kidney disease. "Historically, Clinicians called elevated brachial pressure (measured with a cuff at the arm) 'The Silent Killer' because it is asymptomatic and life-threatening," said Duncan Ross. "Elevated central blood pressure is 'The Very Silent Killer' because it may go undetected with traditional cuff blood pressure measurements, and studies show it is over 50% more effective as a predictor of cardiovascular events. Studies also show that patients with elevated central pressure are at higher risk of these events, even when hypertension detected at the arm has been medically controlled. The published science clearly supports the need to measure central blood pressure in at risk and questionable patient populations," he concluded.
About AtCor Medical
AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure noninvasively. The company's SphygmoCor system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 1,700 SphygmoCor systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in over 400 peer-reviewed studies published in leading medical journals. AtCor Medical has operations in Australia, the United States and Europe. For further information, please visit out web site at www.atcormedical.com
Source: AtCor Medical Holdings
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.